TLDR
- VEEV shares climbed approximately 12% following a strong Q4 earnings report, delivering EPS of $2.06 versus analyst expectations of $1.94.
- Quarterly revenue reached $836 million, representing 16% year-over-year growth and surpassing the $811 million consensus.
- First quarter outlook calls for $2.13–$2.14 EPS and $855–$858 million in revenue, both exceeding Street projections.
- Full-year 2027 revenue forecast of $3.585–$3.6 billion comes in above the $3.56 billion analyst consensus.
- The company secured commitments from ten of the largest 20 biopharma firms for its Vault CRM solution.
Veeva Systems entered 2026 on shaky ground, with shares declining 16% prior to its earnings announcement. Wednesday evening’s report flipped the script entirely.
The company’s fourth quarter performance significantly exceeded analyst projections. Adjusted earnings per share reached $2.06, surpassing the $1.94 consensus forecast. Revenue expanded 16% from the prior year to $836 million, beating the $811 million estimate.
Investors reacted swiftly. VEEV shares jumped approximately 12% during Thursday’s early session.
The positive momentum extended beyond historical results. Management’s forward-looking projections provided additional fuel for bullish sentiment.
For the first quarter, Veeva projects EPS between $2.13 and $2.14, exceeding Wall Street’s $2.10 expectation. The revenue outlook of $855 to $858 million also surpassed the $853 million consensus.
Looking at the complete fiscal year 2027, management forecasted revenue ranging from $3.585 to $3.6 billion. This guidance exceeded the analyst consensus of $3.56 billion. The company’s non-GAAP EPS projection of $8.85 similarly topped expectations of $8.60.
The billings forecast caught significant analyst attention. KeyBanc’s Scott Schoenhaus highlighted the “healthy billings guidance” as a factor supporting the stock’s valuation amid widespread software sector weakness.
Schoenhaus, who maintains a Sector Weight rating on VEEV, suggested the results should alleviate investor worries surrounding the broader software industry selloff linked to emerging AI coding technologies.
The CRM Commitment
One particular metric from the earnings report commanded attention. Veeva disclosed that 10 of the 20 largest biopharmaceutical companies have now adopted its Vault CRM platform.
This represents tangible evidence of traction in a critical product category.
Vault CRM targets the unique needs of life sciences organizations, managing regulatory and operational processes that generic CRM solutions struggle to address effectively. Securing commitments from major pharmaceutical players is typically a lengthy sales cycle — making these wins particularly meaningful.
Veeva’s financial metrics reinforce the growth narrative. The company maintains a net margin of 27.93% and an impressive gross margin of 75.67%. Its current ratio stands at 7.53 while the debt-to-equity ratio registers just 0.01.
By any standard, this represents exceptional balance sheet strength.
Valuation Check
Prior to the post-earnings surge, VEEV’s P/E ratio of 36.67 hovered near its lowest level in a decade. The P/S ratio of 10.25 and P/B ratio of 4.4 similarly traded near multi-year lows.
Wall Street’s consensus price target of $292.17 indicated substantial upside from pre-earnings levels.
Institutional investors hold 86.51% of shares outstanding, demonstrating significant confidence from major fund managers. Insider ownership sits at 7.59%, with company insiders selling 1,000 shares over the trailing three-month period.
The company has delivered a three-year revenue growth rate of 13.4%, while its Altman Z-Score of 19.88 signals robust financial stability.
As of Thursday morning, VEEV shares traded near $201.33, marking a significant advance from approximately $188 before the earnings release.
